The earnings call reflects a positive overall sentiment driven by strong growth in the innovative portfolio and strategic advancements in the pipeline, despite challenges in the generics market and uncertainties regarding tariffs.

Company Guidance -

Q3 2025

During the Teva Pharmaceutical Industries Limited Q2 2025 earnings call, the company reported a solid financial performance, highlighting several key metrics. Revenues rose to $4.2 billion, marking the 10th consecutive quarter of growth with a 1% increase, driven by strong performances from their innovative portfolio, including AUSTEDO, AJOVY, and UZEDY. AUSTEDO's revenue surged by 19% to just below $500 million, UZEDY increased by 120% to $54 million, and AJOVY saw a 31% growth reaching $155 million. The adjusted EBITDA grew by 7%, while the non-GAAP EPS increased by 10%. The company's net debt to EBITDA ratio stood just over 3. Despite a decline in their Global Generics business by 2%, Teva reiterated confidence in their 2027 targets, projecting mid-single-digit average growth rates and aiming to achieve net savings of $700 million through their transformation programs.

Innovative Portfolio Growth

AUSTEDO grew 22% in the U.S. to $495 million, UZEDY up 120% to $54 million, and AJOVY up 31% to $155 million. The innovative portfolio is expected to overdeliver with an additional $95 million for the year.

10th Consecutive Quarter of Growth

Teva reported its 10th consecutive quarter of growth with revenues up to $4.2 billion, an increase of 1% in local currency.

Improved Financial Metrics

Adjusted EBITDA increased by 7%, non-GAAP EPS up by 10%, and free cash flow grew by 47% to $476 million.

Biosimilars and Complex Generics Pipeline

Teva is on track to launch 15 complex generics and 8 biosimilars between now and 2027.

Teva Transformation Program

The company is on track to achieve $700 million in net savings by 2027, with 20% of the targeted savings already realized.

Pipeline Progress

Strong late-stage pipeline with potential peak sales over $10 billion, including products like duvakitug and anti-IL-15.

Balance Sheet Strengthening

Teva refinanced $2.3 billion of debt maturities, reducing gross debt to $17.2 billion and maintaining net debt to EBITDA just over 3x.

Teva Pharmaceutical (TEVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TEVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.68 / -	0.69	―	―	―
Jul 30, 2025	2025 (Q2)	0.62 / 0.66	0.61	8.20% (+0.05)
May 07, 2025	2025 (Q1)	0.46 / 0.52	0.48	8.33% (+0.04)
Jan 29, 2025	2024 (Q4)	0.71 / 0.71	1	-29.00% (-0.29)
Nov 06, 2024	2024 (Q3)	0.66 / 0.69	0.6	15.00% (+0.09)
Jul 31, 2024	2024 (Q2)	0.55 / 0.61	0.56	8.93% (+0.05)
May 08, 2024	2024 (Q1)	0.51 / 0.48	0.4	20.00% (+0.08)
Jan 31, 2024	2023 (Q4)	0.77 / 1.00	0.71	40.85% (+0.29)
Nov 08, 2023	2023 (Q3)	0.61 / 0.60	0.59	1.69% (+0.01)
Aug 02, 2023	2023 (Q2)	0.53 / 0.56	0.68	-17.65% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TEVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$16.54	$16.83	+1.75%
May 07, 2025	$16.12	$17.60	+9.18%
Jan 29, 2025	$21.53	$18.54	-13.89%
Nov 06, 2024	$18.77	$17.43	-7.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.